Please assess the completion status of the following clinical trial:

Trial Title: Aflibercept in Polypoidal Choroidal Vasculopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Men and women ≥50 years of age~* Diagnosis of symptomatic macular Polypoidal Choroidal Vasculopathy (PCV) in the study eye established by Indocyanine Green Angiography(ICGA) at the study center~* Greatest linear dimension of the lesion of \< 5400 mm (approximately, 9 Macular Photocoagulation Study disk areas), assessed by ICGA.~* An Early treatment diabetic retinopathy study (ETDRS) BCVA of 73 to 24 letters in the study eye.~Exclusion Criteria:~* Prior use of intravitreal or sub-tenon corticosteroids in the study eye within 3 months prior to study entry~* Any prior use of intraocular anti Vascular Endothelial Growth Factor (anti-VEGF)agents in the study eye, or systemic use of anti VEGF products within 3 months prior to study entry~* Prior macular laser treatment in the study eye including Photodynamic Therapy (PDT)~* History of allergy to fluorescein used in fluorescein angiography, iodine and/or indocyanine green.~* History of allergy to aflibercept, verteporfin, or their excipients.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept + Sham PDT (Type: EXPERIMENTAL): Participants received 2 milligram (mg) Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus sham photodynamic therapy (only in subjects qualifying for rescue therapy)
- Aflibercept + Active PDT (Type: EXPERIMENTAL): Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus active photodynamic therapy (only in subjects qualifying for rescue therapy)

Based on this trial design, predict the completion outcome and termination type (if applicable).